Syncona’s Autolus and BioNTech forge alliance to propel CAR-T therapies
Syncona Ltd, a prominent investor in the life sciences sector, has announced a significant strategic collaboration through its portfolio company, Autolus Therapeutics plc, with BioNTech SE, a trailblazer in next-generation immunotherapies. This partnership marks a pivotal step towards the commercialization of autologous CAR-T programs, pending regulatory approvals. BioNTech’s investment of $200 million in Autolus’ American […]